Lineage Cell Therapeutics (LCTX) P/E (2011 - 2026)
Lineage Cell Therapeutics (LCTX) P/E from Mar 31, 2011 to Jul 21, 2026. The TTM Lineage Cell Therapeutics (LCTX) P/E is -4.08. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
P/E
Annual P/E change of Lineage Cell Therapeutics (LCTX)
| Year | P/E | Change |
|---|---|---|
| 2026 | -4.08 | -32.32% |
| 2025 | -6.02 | +2.91% |
| 2024 | -5.85 | -37.24% |
| 2023 | -9.32 | +101.06% |
| 2022 | -4.64 | -57.79% |
| 2021 | -10.99 | -24.61% |
| 2020 | -14.57 | +11.15% |
| 2019 | -13.11 | +354.53% |
| 2018 | -2.88 | -151.11% |
| 2017 | 5.64 | -70.23% |
| 2016 | 18.96 | -348.07% |
| 2015 | -7.64 | +1.13% |
| 2014 | -7.56 | +53.02% |
| 2013 | -4.94 | -36.91% |
| 2012 | -7.83 | -70.88% |
| 2011 | -26.88 | N/A |
Comparison Lineage Cell Therapeutics (LCTX) P/E with competitors
Lineage Cell Therapeutics (LCTX) P/E is -4.08.